During the past decade, Klinische Forschung Berlin GbR conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 6 clinical trials were completed, i.e. on average, 31.6% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 4 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Klinische Forschung Berlin GbR" #1 sponsor was "Boehringer Ingelheim" with 6 trials, followed by "Amgen" with 3 trials sponsored, "Pfizer" with 3 trials sponsored, "Enzymatica AB" with 2 trials sponsored and "Applied Therapeutics, Inc." with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klinische Forschung Berlin GbR" #1 collaborator was "Analyze & Realize" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "ClinPhone, Inc." with 1 trials as a collaborator, "Coordinating Centre for Clinical Trials, Charité" with 1 trials as a collaborator and "Covance" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Klinische Forschung Berlin GbR" are "Pulmonary Disease, Chronic Obstructive" (3 trials), "Common Cold" (2 trials), "Heart Failure" (2 trials), "Obesity" (2 trials) and "Smoking Cessation" (2 trials). Many other conditions were trialed in "Klinische Forschung Berlin GbR" in a lesser frequency.

Most popular intervention types in "Klinische Forschung Berlin GbR" are "Drug" (17 trials), "Biological" (4 trials), "Device" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "ColdZyme" (2 trials), "Empagliflozin" (2 trials), "Evolocumab" (2 trials) and "Olodaterol" (2 trials). Other intervention names were less common.

The vast majority of trials in "Klinische Forschung Berlin GbR" are 24 trials for "All" genders.

Currently, there are NaN active trials in "Klinische Forschung Berlin GbR". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Klinische Forschung Berlin GbR, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Klinische Forschung Berlin GbR, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 3 trials that are defined as “Not Applicable".